Market capitalization | $557.49m |
Enterprise Value | $246.98m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.67 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-131.60m |
Free Cash Flow (TTM) Free Cash Flow | $-105.48m |
Cash position | $340.12m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
8 Analysts have issued a Annexon Inc forecast:
8 Analysts have issued a Annexon Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.41 -3.41 |
1%
1%
|
|
EBITDA | -128 -128 |
13%
13%
|
EBIT (Operating Income) EBIT | -132 -132 |
13%
13%
|
Net Profit | -118 -118 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Douglas Love |
Employees | 71 |
Founded | 2011 |
Website | www.annexonbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.